Showing 6141-6150 of 7666 results for "".
- OMNY Health Launches Integrated Dermatology Data Repository and Research Networkhttps://practicaldermatology.com/news/omny-health-launches-integrated-dermatology-data-repository-and-research-network/2460845/OMNY Health has partnered with community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research. The assembled longitudinal data represents care delivered over the pas
- DermTech Fills Three Leadership Postshttps://practicaldermatology.com/news/dermtech-fills-three-leadership-posts/2460843/With three new appointments, DermTech has filled key leadership roles at the company. Loren Clarke, MD is now Chief Medical Officer, Ray Bassi is Vice President, Sales, and Patrick Johnson is Vice President, Information Technology and Digital Systems. Dr. Clarke, a board-ce
- Research Brief: Personalized Bacteriotherapy May Improve Skin Microbiome and Symptoms in ADhttps://practicaldermatology.com/news/research-brief-personalized-bacteriotherapy-may-improve-skin-microbiome-and-symptoms-in-ad/2460841/Bacteriotherapy with an autologous strain of bacteria may safely improve S. aureus colonization in the microbiome of patients with atopic dermatitis (AD) and improve disease severity, a
- FDA Approves StrataGraft for the Treatment of Adults with Thermal Burnshttps://practicaldermatology.com/news/fda-approves-stratagraft-for-the-treatment-of-adults-with-thermal-burns/2460839/The U.S. Food and Drug Administration approved StrataGraft for the treatment of adult deep partial thickness burns. "Serious burns can be an incredibly difficult injury to treat and can adversely affect more than just the skin. The goal of burn management is to help the patient ret
- Nutrafol Launches Postpartum Formulahttps://practicaldermatology.com/news/nutrafol-launches-postpartum-formula/2460838/The first-of-its-kind postpartum hair nutraceutical is now available from Nutrafol. Nutrafol Postpartum was developed with an OB/GYN to target the root causes of excess hair shedding and thinning post-pregnancy. It is intended to help the body recover from the physical stress of childbirth,
- Water's Edge Partners with Goodman Dermatologyhttps://practicaldermatology.com/news/waters-edge-partners-with-goodman-dermatology/2460837/Water’s Edge Dermatology has partnered with Goodman Dermatology, P.C., a general and cosmetic dermatology practice in Atlanta. Water’s Edge Dermatology recently merged with Riverchase Dermatology (collectively, “WED/RCD”) and is a leading provider of compreh
- FDA Approves Expanded Use of the RECELL System for Extensive Burns and Pediatric Patientshttps://practicaldermatology.com/news/fda-approves-expanded-use-of-the-recell-system-for-extensive-burns-and-pediatric-patients/2460831/The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. Specifically, RECELL is now in
- Merz Aesthetics Launches New Online Aesthetics Education Platformhttps://practicaldermatology.com/news/merz-aesthetics-launches-new-online-aesthetics-education-platform/2460830/Merz Aesthetics is launching Merz Aesthetics Medical Forum, an online medical aesthetics education platform for health care professionals around the world. Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthe
- FDA Grants Breakthrough Device Status to Alpha DaRT for SCChttps://practicaldermatology.com/news/fda-grants-breakthrough-device-status-to-alpha-dart-for-scc/2460829/The U.S. Food and Drug Administration (FDA) granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma (SCC) of the skin and oral cavity without curative standard of care. Alpha Tau submitted data to the FDA supporting this de
- EULAR: Data Show Benefit of Tremfya in PsA After Anti-TNF Failurehttps://practicaldermatology.com/news/eular-day-shown-benefit-of-tremfya-in-psa-after-anti-tnf-failure/2460834/New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Trem